Bridging phenotype and function in bladder cancer using immuno-competent organoids and ex vivo drug screening
Abstract Background Bladder cancer (BLC) remains a clinically challenging malignancy due to its pronounced inter- and intra-patient heterogeneity, which contributes to therapeutic resistance and poor clinical outcomes. Capturing and modeling this complexity is essential for the development of effect...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BMC
2026-04-01
|
| Cyfres: | Journal of Experimental & Clinical Cancer Research |
| Pynciau: | |
| Mynediad Ar-lein: | https://doi.org/10.1186/s13046-026-03701-x |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
